Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2013 1
2014 1
2015 1
2016 2
2017 1
2018 3
2021 1
Text availability
Article attribute
Article type
Publication date

Search Results

9 results
Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone.
Gnant M, Filipits M, Greil R, Stoeger H, Rudas M, Bago-Horvath Z, Mlineritsch B, Kwasny W, Knauer M, Singer C, Jakesz R, Dubsky P, Fitzal F, Bartsch R, Steger G, Balic M, Ressler S, Cowens JW, Storhoff J, Ferree S, Schaper C, Liu S, Fesl C, Nielsen TO; Austrian Breast and Colorectal Cancer Study Group. Gnant M, et al. Ann Oncol. 2014 Feb;25(2):339-45. doi: 10.1093/annonc/mdt494. Epub 2013 Dec 16. Ann Oncol. 2014. PMID: 24347518 Free article.
BACKGROUND: PAM50 is a 50-gene test that is designed to identify intrinsic breast cancer subtypes and generate a Risk of Recurrence (ROR) score. ...The primary analysis was designed to test whether the continuous ROR score adds prognostic value in p
BACKGROUND: PAM50 is a 50-gene test that is designed to identify intrinsic breast cancer subtypes and generate a Risk o …
Clinical relevance of the 21-gene Recurrence Score() assay in treatment decisions for patients with node-positive breast cancer in the genomic era.
Mamounas EP, Russell CA, Lau A, Turner MP, Albain KS. Mamounas EP, et al. NPJ Breast Cancer. 2018 Aug 20;4:27. doi: 10.1038/s41523-018-0082-6. eCollection 2018. NPJ Breast Cancer. 2018. PMID: 30155517 Free PMC article. Review.
Genomic information augments the prognostic information gleaned from clinico-pathologic features by providing risk estimates for distant recurrence and/or breast cancer-specific survival based on individual tumor biology. The 21-gene Oncotype DX …
Genomic information augments the prognostic information gleaned from clinico-pathologic features by providing risk estimates for d
Development of a Novel Proteomic Risk-Classifier for Prognostication of Patients With Early-Stage Hormone Receptor-Positive Breast Cancer.
Ramkumar C, Buturovic L, Malpani S, Kumar Attuluri A, Basavaraj C, Prakash C, Madhav L, Doval DC, Mehta A, Bakre MM. Ramkumar C, et al. Biomark Insights. 2018 Jul 30;13:1177271918789100. doi: 10.1177/1177271918789100. eCollection 2018. Biomark Insights. 2018. PMID: 30083053 Free PMC article.
Use of proteomic strategies to identify a risk classifier that estimates probability of distant recurrence in early-stage hormone receptor (HR)-positive breast cancer is relevant to physiological cellular function and therefore to …
Use of proteomic strategies to identify a risk classifier that estimates probability of distant recurrence in early-sta …
Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5.
Dowsett M, Sestak I, Regan MM, Dodson A, Viale G, Thürlimann B, Colleoni M, Cuzick J. Dowsett M, et al. J Clin Oncol. 2018 Jul 1;36(19):1941-1948. doi: 10.1200/JCO.2017.76.4258. Epub 2018 Apr 20. J Clin Oncol. 2018. PMID: 29676944 Free PMC article. Clinical Trial.
Purpose Estimating risk of late distant recurrence (DR) is an important goal for managing women with hormone receptor-positive breast cancer after 5 years of endocrine treatment without recurrence. ...From years 5 to 10, 63% …
Purpose Estimating risk of late distant recurrence (DR) is an important goal for managing women with hormone recepto
The Role of the 21-Gene Recurrence Score in Breast Cancer Treatment.
Ethier JL, Amir E. Ethier JL, et al. Mol Diagn Ther. 2016 Aug;20(4):307-13. doi: 10.1007/s40291-016-0209-0. Mol Diagn Ther. 2016. PMID: 27235162 Review.
Several multi-gene assays have been developed to predict the risk of recurrence in patients with estrogen receptor-positive early breast cancer and in whom endocrine therapy is planned. The 21-gene assay is widely used and i …
Several multi-gene assays have been developed to predict the risk of recurrence in patients with estrogen rec
The impact of the 21-gene recurrence score assay on decision making about adjuvant chemotherapy in early-stage estrogen-receptor-positive breast cancer in an oncology practice with a unified treatment policy.
Geffen DB, Abu-Ghanem S, Sion-Vardy N, Braunstein R, Tokar M, Ariad S, Delgado B, Bayme M, Koretz M. Geffen DB, et al. Ann Oncol. 2011 Nov;22(11):2381-2386. doi: 10.1093/annonc/mdq769. Epub 2011 Mar 1. Ann Oncol. 2011. PMID: 21363879 Free article.
BACKGROUND: The 21-gene recurrence score (RS) assay has been validated in retrospective studies as prognostic of distant disease recurrence and predictive of the benefit of adjuvant chemotherapy in estrogen-receptor-positive breast
BACKGROUND: The 21-gene recurrence score (RS) assay has been validated in retrospective studies as prognostic of distant disea …
A novel immune prognostic index for stratification of high-risk patients with early breast cancer.
Lee H, Kwon MJ, Koo BM, Park HG, Han J, Shin YK. Lee H, et al. Sci Rep. 2021 Jan 8;11(1):128. doi: 10.1038/s41598-020-80274-5. Sci Rep. 2021. PMID: 33420250 Free PMC article.
The prognostic value of current multigene assays for breast cancer is limited to hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer. ...Here, using public gene expression microar …
The prognostic value of current multigene assays for breast cancer is limited to hormone receptor-positive
Prognostic and predictive indicators in early-stage breast cancer and the role of genomic profiling: Focus on the Oncotype DX() Breast Recurrence Score Assay.
Curtit E, Mansi L, Maisonnette-Escot Y, Sautière JL, Pivot X. Curtit E, et al. Eur J Surg Oncol. 2017 May;43(5):921-930. doi: 10.1016/j.ejso.2016.11.016. Epub 2016 Dec 14. Eur J Surg Oncol. 2017. PMID: 28087099 Review.
Although useful prognostic and predictive insights can be gained from patient and tumour characteristics in early-stage breast cancer, it is not always straightforward to predict the likely risk of recurrence for each individual …
Although useful prognostic and predictive insights can be gained from patient and tumour characteristics in early-stage bre
Effect of 21-Gene RT-PCR Assay on Adjuvant Therapy and Outcomes in Patients With Stage I Breast Cancer.
Le Du F, Gonzalez-Angulo AM, Park M, Liu DD, Hortobagyi GN, Ueno NT. Le Du F, et al. Clin Breast Cancer. 2015 Dec;15(6):458-66. doi: 10.1016/j.clbc.2015.06.006. Epub 2015 Jun 18. Clin Breast Cancer. 2015. PMID: 26233757 Free PMC article.
BACKGROUND: Recurrence score (RS) derived from a 21-gene reverse transcriptase-polymerase chain reaction assay is used to stratify patients with early-stage estrogen receptor-positive, HER2-normal breast cancer into 3 groups on the basis …
BACKGROUND: Recurrence score (RS) derived from a 21-gene reverse transcriptase-polymerase chain reaction assay is used to stratify …